Janneke Meulenberg, Ph.D.

Janneke Meulenberg has 20+ years of experience in leadership positions in the Biopharmaceutical industry. Prior to joining ORCA, she was a management team member of Amsterdam Molecular Therapeutics  (AMT: now UniQure). She was responsible for successful development of AMT’s lead product Glybera® , the first gene therapy to receive market approval in the Western World. At ID-Lelystad, Janneke headed a world leading R&D team to develop veterinary vaccines in collaboration with Boehringer Ingelheim. She graduated cum laude, received a PhD in Biochemistry and holds an MBA from RSM Erasmus University. She is author of numerous peer-reviewed publications and book chapters, and inventor on several patents.

Ramon Alemany, Ph.D.

Ramon Alemany is laboratory director in the Catalan Institute of Oncology (ICO), Barcelona, Spain. He has held various research positions at MD Anderson Cancer Center, Baxter Healthcare (Round Lake, IL) and the University of Alabama. He is author of more than 50 original publications in the field of gene therapy and virotherapy with adenoviruses, patents, reviews and book chapters and is reviewer for different journals and (inter)national granting agencies. He has been member of the Executive Board of Spanish Society of Gene and Cell Therapy, consultant of companies involved in adenovirus vector development, and he is on the Scientific Advisory Board of Oncolytics Biotech Inc. and chairman of the scientific committee of VCN Biosciences.

Professor Winald Gerritsen, MD, Ph.D.

Winald Gerritsen is a medical oncologist and professor in tumor Immunology at the Radboud University Nijmegen Medical Centre. He has a strong background in translational research. Following his medical training at the University of Nijmegen, Prof. Gerritsen achieved his PhD in 1989 on bone marrow transplantation at the Medical School of the Erasmus University of Rotterdam. From 1989 till 1991 he worked as a special fellow at Memorial Sloan Kettering Cancer Center in New York, after which he held several positions at respectively the University Hospital Utrecht, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital and the VU University Medical Center, where he was Director of the VUmc Cancer Center Amsterdam. As principal investigator, he has been involved in a variety of (clinical) studies with immunotherapeutic compounds.

Professor Frank McCormick, Ph.D.

Frank McCormick is Professor Emeritus of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work in various positions at Cetus Corporation (Director of Molecular Biology and Vice President of Research) and Chiron Corporation, where he was Vice President of Research. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, where he served as Chief Scientific Officer. His drug discovery efforts at Onyx Pharmaceuticals led to the approval of Sorafenib for treatment of renal cell cancer and liver cancer, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. He is the author of over 285 scientific publications and holds 20 issued patents. Prof. McCormick received his PhD in 1975 at the University of Cambridge, England.

Professor Ronald Rodriguez, MD, Ph.D.

Ronald Rodriguez is Professor and Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio. He is a world expert in the use of cryoablative technologies for kidney and recurrent prostate cancer. He obtained his PhD and MD from Baylor College of Medicine. After medical school, Dr. Rodriguez entered Johns Hopkins University School of Medicine, where he stayed on faculty up to 2012. During his last seven years at Johns Hopkins, he was the program director for urology training. In January 2013, he moved to the University of Texas Health Science Center. Dr. Rodriguez is a highly experienced urologic surgeon with expertise in urologic oncology, particularly focusing on prostate and kidney cancer. His research group is internationally recognized in the development of adenoviral gene- and virotherapy for urologic malignancies.